Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome.

No abstract is available for this paper.

• Publication year

  1985

• Venue

  New England Journal of Medicine

• Publication date

  1985-12-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1056/NEJM198512053132301PMID 3864009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

  2005cited by this paper
• Structural organization of the bcr gene and its role in the Ph′ translocation

  1985cited by this paper
• C‐abl and bcr are rearranged in a Ph1‐negative CML patient.

  1985cited by this paper
• The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity.

  1985cited by this paper
• Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes

  1985cited by this paper
• Unusual translocations involving chromosomes 12;22 and 9;12 in a case of chronic myelogenous leukemia.

  1985cited by this paper
• Current Status of Treatment of Acute Leukemia in Adults: An Overview

  1984cited by this paper
• Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.

  1984cited by this paper
• Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

  1984cited by this paper
• Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences

  1984cited by this paper
• Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells.

  1984cited by this paper
• Altered transcription of an oncogene in chronic myeloid leukaemia.

  1984cited by this paper
• An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

  1984cited by this paper
• The mouse c-abl locus: molecular cloning and characterization.

  1984cited by this paper
• An 8-kilobase abl RNA transcript in chronic myelogenous leukemia.

  1984cited by this paper
• The human v-abl cellular homologue.

  1983cited by this paper
• A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells.

  1983cited by this paper
• Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

  1983cited by this paper
• A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

  1982cited by this paper
• Evidence that the Abelson virus protein functions in vivo as a protein kinase that phosphorylates tyrosine.

  1981cited by this paper
• The nonstructural components of polyproteins encoded by replication-defective mammalian transforming retroviruses are phosphorylated and have associated protein kinase activity.

  1980cited by this paper
• Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

  1975cited by this paper
• A simple R banding technic.

  1975cited by this paper
• In vitro transformation of lymphoid cells by Abelson murine leukemia virus.

  1975cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper
• Lymphosarcoma: virus-induced thymic-independent disease in mice.

  1970cited by this paper

• Treatment of Philadelphia-Positive Acute Lymphoblastic Leukemia

  2025cites this paper
• How I treat Ph+ acute lymphoblastic leukemia.

  2025cites this paper
• BCR-ABL: The molecular mastermind behind chronic myeloid leukemia.

  2025cites this paper
• Ph-Positive Acute Lymphoblastic Leukemia - 25 Years of Progress.

  2025cites this paper
• Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity

  2025cites this paper
• Oncofusions – shaping cancer care

  2024cites this paper
• Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways

  2023cites this paper
• Decoding Oncofusions: Unveiling Mechanisms, Clinical Impact, and Prospects for Personalized Cancer Therapies

  2023cites this paper
• Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance

  2022cites this paper
• Non-coding RNAs: are they the protagonist or antagonist in the regulation of leukemia?

  2022cites this paper
• Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future

  2021cites this paper
• Gene Duplication and Gene Fusion Are Important Drivers of Tumourigenesis during Cancer Evolution

  2021cites this paper
• A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.

  2021cites this paper
• CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia

  2021cites this paper
• CRISPR/Cas9 technology abolishes the BCR/ABL1 oncogene in chronic myeloid leukemia and restores normal hematopoiesis

  2020cites this paper
• Myeloproliferative neoplasms

  2020cites this paper
• Genomic and Transcriptomic Analyses of Osteogenic Tumours of Bone

  2020cites this paper
• FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention

  2020cites this paper
• Introduction to hematologic neoplasms

  2020cites this paper
• An in silico design of bioavailability for kinase inhibitors evaluating the mechanistic rationale in the CYP metabolism of erlotinib

  2019cites this paper
• Detection of BCR/ABL Fusion Gene in Chronic Myeloid Leukaemia Using Reverse Transcriptase Polymerase Chain Reaction

  2019cites this paper
• Targeting chromatin complexes in fusion protein-driven malignancies

  2019cites this paper
• Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells.

  2018cites this paper
• RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice Variants.

  2018cites this paper
• CircBA9.3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels.

  2018cites this paper
• Revisiting the need for bone marrow examination in chronic myeloid leukemia

  2018cites this paper
• Comprehensive analysis of structural genomic alterations in cancer

  2018cites this paper
• A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015

  2017cites this paper
• OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes

  2017influential citation
• Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine

  2017cites this paper
• An investigation of metabolic vulnerabilities in chronic myeloid leukaemic stem cells

  2017cites this paper
• Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes

  2017cites this paper
• Chronic myeloid leukemia: reminiscences and dreams

  2016cites this paper
• The second hit of DNA methylation

  2016cites this paper
• Myeloproliferative neoplasms: A decade of discoveries and treatment advances

  2016cites this paper
• SplitThreader: Exploration and analysis of rearrangements in cancer genomes

  2016cites this paper
• SRC Oncogene to Chromosome Band 20q1 1.2 and Loss of This Gene With Deletion (20q) in Two Leukemic Patients

  2016cites this paper
• Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival

  2015cites this paper
• Chronic myeloid leukemia

  2015cites this paper
• The emerging complexity of gene fusions in cancer

  2015cites this paper
• phosphorylation.of Bcr serine kinase by tyrosine

  2013cites this paper
• CENTRO UNIVERSITÁRIO DE BRASÍLIA - UNICEUB FACULDADE DE CIÊNCIAS DA EDUCAÇÃO E SAÚDE - FACES GRADUAÇÃO EM BIOMEDICINA

  2013cites this paper
• Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data

  2013cites this paper
• SYNERGY BETWEEN JAK INHIBITOR RUXOLITINIB AND TYROSINE KINASE INHIBITORS TO OVERCOME DRUG RESISTANCE RELATED TO BONE MARROW STROMA MICROENVIRONMENT IN CHRONIC MYELOID LEUKEMIA

  2013cites this paper
• Implications of a CALM-derived Nuclear Export Signal for CALM-AF10-mediated Leukemogenesis

  2013cites this paper
• New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.

  2012cites this paper
• One thousand patients with primary myelofibrosis: the mayo clinic experience.

  2012cites this paper
• The secret ally: immunostimulation by anticancer drugs

  2012cites this paper
• Genetic aberrations in patients with leukaemia and their impact on prognosis

  2012cites this paper
• Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome.

  2011cites this paper
• Managing resistance in chronic myeloid leukemia.

  2011cites this paper
• Chronic myeloid leukemia

  2011cites this paper
• positive chronic myeloid leukemia Rare occurrence of N-ras point mutations in Philadelphia chromosome

  2011cites this paper
• oncogene in both chronic phase and blast crisis Chronic myelogenous leukemia: amplification of a rearranged c-abl

  2010cites this paper
• Targeted Therapies: The Rare Cancer Paradigm

  2010cites this paper
• 7. Chronic Myeloid Leukemia

  2010cites this paper
• Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib

  2009cites this paper
• Molecular diagnosis of myeloproliferative neoplasms

  2009cites this paper
• Towards cure of CML: why we need to know more about CML stem cells?

  2009cites this paper
• Clinical pharmacokinetics of tyrosine kinase inhibitors.

  2009cites this paper
• Targeting oncogenes with siRNAs.

  2009cites this paper
• Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.

  2009cites this paper
• [The short history of protein kinase inhibitors. New, competitive, successful].

  2008cites this paper
• Identification of fusion genes regulating liver cancer progression through transcript analysis

  2008cites this paper
• Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1

  2008cites this paper
• BCR-ABL-negative atypical chronic myeloproliferative disorders

  2008cites this paper
• The history of myeloproliferative disorders: before and after Dameshek

  2008cites this paper
• Inhibitors of ABL and the ABL-T315I mutation.

  2008cites this paper
• Die kurze Geschichte der Proteinkinase‐Inhibitoren. Jung, kompetitiv, erfolgreich

  2008cites this paper
• Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia.

  2007cites this paper
• Targeted chronic myeloid leukemia therapy: Seeking a cure.

  2007cites this paper
• Spontaneous duplications in diploid Saccharomyces cerevisiae cells.

  2007cites this paper
• Treatment for chronic myelogenous leukemia: the long road to imatinib.

  2007cites this paper
• Oncogenes in Myeloproliferative Disorders

  2007cites this paper
• The legacy of the Philadelphia chromosome.

  2007cites this paper
• Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia

  2006cites this paper
• Klinische Bedeutung des Nachweises minimaler Residualerkrankung bei Leukämien, Lymphomen und soliden Tumoren

  2006cites this paper
• Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system.

  2006cites this paper
• The bcr Gene in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  2005cites this paper
• Analysis of Chromosomal Translocations

  2005cites this paper
• Chromosome-positive Chronic Myelocytic Leukemia T Lymphocytes Lack Rearrangement of the Bcr Gene in Philadelphia

  2005cites this paper
• Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.

  2005cites this paper
• THE ROLE OF SRC FAMILY TYROSINE KINASES IN BCR-ABL SIGNAL TRANSDUCTION AND CHRONIC MYELOGENOUS LEUKEMIA

  2004cites this paper
• Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies

  2003cites this paper
• Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development.

  2003cites this paper
• Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors.

  2003cites this paper
• Validation of sixteen leukemia and lymphoma cell lines as controls for molecular gene rearrangement assays.

  2002cites this paper
• Detection and quantification of leukemia-specific rearrangements.

  2002cites this paper
• Characteristic genome rearrangements in experimental evolution of Saccharomyces cerevisiae

  2002cites this paper
• Symposium 6A: Minimal residual disease in bone marrow disorders

  2002cites this paper
• Genetic and environmental factors in cancer and neurodegenerative diseases.

  2002cites this paper
• Fortuitous convergences: the beginnings of JUN

  2002cites this paper
• Philadelphia-positive leukemia: a personal perspective

  2002cites this paper
• BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations

  2002influential citation
• Actin' up: RhoB in cancer and apoptosis

  2001cites this paper
• Two genetic hits (more or less) to cancer

  2001cites this paper
• The BCR gene and philadelphia chromosome-positive leukemogenesis.

  2001cites this paper
• Detection of minimal residual disease.

  2001cites this paper
• Preparation and application of antibodies to phosphoamino acid sequences.

  2001cites this paper
• MINI-REVIEW Detection and quantification of residual disease in chronic myelogenous leukemia

  2000cites this paper